Editas Medicine, Inc.

Editas Medicine reported a significant reduction in net loss for the second quarter of 2026, narrowing to $18.23 million from $53.24 million in the prior year. Collaboration and other research and development revenues saw a substantial increase to $11.89 million. The company bolstered its liquidity by raising $116.9 million in net proceeds from a public offering of common stock and warrants in May 2026, contributing to a total of $211.6 million in cash, cash equivalents, and marketable securities. Editas also suspended its at-the-market equity offering facility and updated its collaboration agreement with Bristol-Myers Squibb.

Editas Medicine reported a significantly reduced net loss of $18.2 million, or $0.15 per share, for the second quarter of 2026, an improvement from $53.2 million in the prior year. The company also provided positive updates on its EDIT-401 program, including strong preclinical data showing significant reductions in atherogenic lipoproteins and plans for a Clinical Trial Notification submission this month. A recent public offering raised $125.0 million, bolstering the company's cash position to $211.6 million and extending its cash runway into the second half of 2028.

Editas Medicine, Inc. announced an update to its presentation schedule at the 2026 Jefferies Global Healthcare Conference. The company will now present on Thursday, June 4, 2026, at 2:00 p.m. ET. Investors can access a live webcast of the presentation via the "Investors" section of Editas Medicine's website, with an archived replay available for about 30 days following the event.

Editas Medicine announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants. Each share and warrant are being sold together at a combined public offering price of $2.25, expecting to generate approximately $125.0 million in gross proceeds. If all common stock warrants are exercised at $3.50 per share, the Company would receive an additional $194.4 million. The warrants' expiry is tied to Phase 1 clinical data for EDIT-401 or three years from issuance.

Editas Medicine, Inc. has suspended and terminated the prospectus supplement for its "at-the-market" (ATM) offering program with TD Cowen, effective May 26, 2026. The company will not sell any more common stock under this program until a new prospectus or supplement is filed and declared effective by the SEC. Prior to this suspension, Editas Medicine had issued and sold 14,327,365 shares of common stock, generating aggregate gross proceeds of $43.9 million. The underlying Sales Agreement with TD Cowen remains in full force and effect.

Editas Medicine, a pioneering gene editing company, has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares) and accompanying warrants. All of the securities in the offering are to be sold by Editas Medicine. Cantor and Wells Fargo Securities are serving as joint book-running managers for the proposed offering, which is subject to market and other conditions.

Editas Medicine presented new preclinical data for EDIT-401 at the 94th European Atherosclerosis Society Congress, demonstrating robust reductions of approximately 90% or greater in LDL-C, Lp(a), and ApoB in non-human primates. The company plans to submit a Clinical Trial Notification in Australia by mid-2026 to initiate a first-in-human clinical trial for EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia later in 2026, with early human proof-of-concept data expected by year-end. Editas Medicine also received positive pre-IND feedback from the U.S. FDA, supporting its clinical development strategy.

Editas Medicine presented new preclinical data for EDIT-401, its lead in vivo development candidate, showing robust reductions of approximately 90% in LDL-cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) in non-human primates. These results support its potential as a best-in-class medicine for hyperlipidemia through LDLR upregulation. The company plans to submit a Clinical Trial Notification (CTN) by mid-2026 to initiate a first-in-human clinical trial in Australia for patients with Heterozygous Familial Hypercholesterolemia (HeFH), with early human proof-of-concept data anticipated by the end of 2026.

Editas Medicine reported new preclinical data for its lead candidate, EDIT-401, at the ASGCT 2026 Annual Meeting. A single dose of EDIT-401 achieved a 90% or greater mean LDL cholesterol reduction in non-human primates, with durable effects for approximately six months and a promising safety profile. The data supports EDIT-401's potential as a one-time treatment for hyperlipidemia and its advancement towards clinical development, also highlighting the broader potential of the company's upregulation strategy.

Editas Medicine shared new preclinical data for its lead in vivo development candidate, EDIT-401, supporting its potential as a one-time treatment for hyperlipidemia. The data, presented at ASGCT and TIDES USA 2026, demonstrated a rapid and durable ">=90%" mean LDL-C reduction in non-human primates for "~6 months" with a promising safety profile. These findings strengthen confidence in EDIT-401's advancement toward first-in-human clinical development and highlight the broader potential of the Company's upregulation strategy.